What's in Hospices Civils de Lyon's pipeline?

Hospices Civils de Lyon has 118 drugs in our index: 15 marketed, 0 filed, 20 in Phase 3, 50 in Phase 2, 33 in Phase 1.

Which companies overlap with Hospices Civils de Lyon's portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, Sanofi, Memorial Sloan Kettering Cancer Center, University of California, San Francisco, Peking Union Medical College Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hospices-civils-de-lyon.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Hospices Civils de Lyon — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hospices Civils de Lyon pipeline: 15 marketed, 0 filed, 20 Phase 3, 50 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

15 marketed 0 filed 20 Phase 3 50 Phase 2 33 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
blood sample	blood sample	marketed
Placebo of Perindopril (P1)	Placebo of Perindopril (P1)	marketed
parenteral nutrition	parenteral nutrition	marketed	Nutritional support therapy		Nutritional support / Critical care
DARATUMUMAB (DARZALEX®)	DARATUMUMAB (DARZALEX®)	marketed	CD38-targeting monoclonal antibody	CD38	Oncology
Perindopril (T1)	Perindopril (T1)	marketed	ACE inhibitor	Angiotensin-converting enzyme (ACE)	Cardiovascular
Cabozantinib group	Cabozantinib group	marketed
CLARA	CLARA	marketed			Other
Indapamide (T2)	Indapamide (T2)	marketed	Thiazide-like diuretic	Sodium-chloride cotransporter (NCC)	Cardiovascular
tocopherol alpha	tocopherol alpha	marketed
pirfenidone and nintedanib	pirfenidone and nintedanib	marketed
PRIVIGEN (CSL Behring)	PRIVIGEN (CSL Behring)	marketed	Intravenous immunoglobulin (IVIg)	Fc receptors, complement system, pathogenic antigens and antibodies	Immunology
Antifungal treatment	Antifungal treatment	marketed	Antifungal agent (class varies by specific drug: azole, polyene, echinocandin, or other)		Infectious Disease

Therapeutic area mix

Oncology · 13
Immunology · 4
Cardiovascular · 4
Other · 3
Neurology · 2
Diabetes · 2
Infectious Disease · 2
General Health · 1
Gastroenterology · 1
Immunology / Rheumatology / Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 6 shared drug classes
Sanofi · 5 shared drug classes
Memorial Sloan Kettering Cancer Center · 4 shared drug classes
University of California, San Francisco · 4 shared drug classes
Peking Union Medical College Hospital · 3 shared drug classes
GlaxoSmithKline · 3 shared drug classes
Ahn-Gook Pharmaceuticals Co.,Ltd · 3 shared drug classes
Ain Shams University · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Hospices Civils de Lyon:

Cite this brief

Drug Landscape (2026). Hospices Civils de Lyon — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hospices-civils-de-lyon. Accessed 2026-05-17.